CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital. Pursuant to Belgian ...
In a report released on February 13, Brian Abrahams from RBC Capital maintained a Hold rating on Galapagos (GLPG – Research Report), with a ...
Galapagos (GLPG) stock dips as Morgan Stanley downgrades its rating to Underweight from Equal Weight amid its CAR-T therapy ...
Galapagos NV (GLPG) reports strong financials and strategic advancements amid increased R&D expenses and operational ...
CEO Paul Stoffels highlighted 2024 as a pivotal year for Galapagos, emphasizing the FDA IND clearance for GLPG5101 and strong results from the ATALANTA study in non-Hodgkin lymphoma. He outlined the ...
Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...
NEW YORK – Galapagos said on Monday that it has partnered with NecstGen, a contract development and manufacturing organization (CDMO), to support decentralized manufacturing of Galapagos' cell therapy ...
NecstGen Clean Cleanroom for CAR-T Production NecstGen, a leading Contract Development and Manufacturing Organization (CDMO) dedicated to C ...
1 Day GLPG -1.36% DJIA -0.31% S&P Mid Cap 400 -0.41% Health Care/Life Sciences 0.19% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback